If hepatitis C therapy is so great, why isn't everyone doing it?

HCV therapy is highly effective but underutilized in the transplant setting, likely due to a combination of insurance barriers and lack of adherence to treatment guidelines by transplant professionals. See the article from Axelrod et al on page 2473.

Saved in:
Bibliographic Details
Published in:American journal of transplantation 2018-10, Vol.18 (10), p.2382-2383
Main Author: Brown, Robert S.
Format: Article
Language:English
Subjects:
Antiviral Agents
complication: infectious
economics
editorial/personal viewpoint
health services and outcomes research
Hepacivirus
Hepatitis
Hepatitis C
Humans
infection and infectious agents – viral: hepatitis C
insurance
Kidney Transplantation
kidney transplantation/nephrology
Kidney transplants
liver transplantation/hepatology
Liver transplants
organ transplantation in general
Quality of care
quality of care/care delivery
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HCV therapy is highly effective but underutilized in the transplant setting, likely due to a combination of insurance barriers and lack of adherence to treatment guidelines by transplant professionals. See the article from Axelrod et al on page 2473.
ISSN:1600-6135
1600-6143
DOI:10.1111/ajt.14960